About Us

We believe health care needs to get simpler to get better. To achieve this, we focus on understanding the patient experience and developing new medical devices that help surgeons and their teams be more efficient and effective. We honor the surgical teams who have dedicated their lives to saving yours.

Meet MOLLI

Our flagship product, MOLLI, is easy to use and designed to help surgeons remove lesions more efficiently with increased patient comfort. By utilizing magnetic technology to localize with accuracy and specificity, our solution delivers a better patient experience than traditional wire and other localization options.

MOLLI Marker™

Mark clearly

The MOLLI Marker is non-radioactive and small in size, which provides better patient comfort and allows flexible scheduling of both placement and surgery.

MOLLI Wand™

Detect reliably

The hand-held MOLLI Wand is designed for accurate 3D detection in busy OR environments, offering real-time, precise guidance to the MOLLI Marker.

MOLLI Tablet™

Measure easily

The MOLLI Tablet provides three types of real-time feedback – numeric, visual, and auditory, as the lesion is localized.

MOLLI is not cleared as a medical device for sale in the USA by the FDA, or in Canada by Health Canada.

Meet the MOLLI Team

We’re dedicated to delivering a better patient experience than traditional methods. Let’s chat.

Fazila Seker, PhD

President & CEO

Fazila Seker is passionate about women’s health and social disparity issues within health care. She is the CEO and co-founder of MOLLI Surgical, a company that develops devices to guide precision surgeries for a better patient experience.

She has over twenty years of experience in business venture development, commercial leadership and market strategy in the medical device, energy and specialty materials industries as Program Leader for GE Global Research Center in Niskayuna, NY and Director of Technology and Venture Development for MaRS Innovation in Toronto, Canada. At GE, she created and launched the corporate Nanotechnology program. During her tenure, she successfully generated $10 million in growth funding and was recognized with the GE Management Award for exceptional leadership.

Fazila co-led a breast cancer research initiative that was recognized as one of Canada’s top 10 crowdfunding campaigns by the Globe and Mail.

Dr. Ananth Ravi, PhD, MCCPM

Chief Science & Clinical Officer, Co-founder

In addition to his role at MOLLI Surgical, Dr. Ravi is the Clinical Operations Lead, Brachytherapy and certified medical physicist at Sunnybrook Odette Cancer Centre, with appointments at the University of Toronto, Ryerson University and Sunnybrook Research Institute.

He has a history of research focused on improving image guidance for medical procedures ranging from radiation to surgical oncology techniques. Dr. Ravi has always had an interest in improving the experience of patients undergoing breast-conserving therapy, especially improving the guidance of breast-conserving surgery. He was awarded the Canadian Cancer Society Innovations grant to study the use of magnetic tracking technology for this particular application. This technology was successfully validated and resulted in the creation of MOLLI Surgical.

To this end in a partnership between MOLLI Surgical, Sunnybrook Health Sciences Centre, St. Joseph's Hospital, North York General and Princess Margaret Cancer Centre, Dr. Ravi aims to continue exploring the value of MOLLI through a multi-center clinical trial.

John Dillon, BS

Chief Technology Officer, Co-founder

John is a co-inventor of MOLLI and leads product development and manufacturing. John developed and managed the x-ray safety program and advanced radiation safety and radiation oncology research for Sunnybrook Health Sciences Centre.

John joins MOLLI with over 10 years of experience in engineering high performing technologies and quality control initiatives in the medical and automotive sectors. He holds a degree in medical physics from Ryerson University

Diana Chan, MBA

Chief Marketing Officer

Diana is a medical device executive with over 20 years of experience in sales, marketing and strategic development. She specializes in building and leading synergistic teams and has a proven track record of developing innovative solutions within healthcare environments.

Diana has broad market experience, having founded BridgeGap Solutions Group to provide business and market development support to organizations with limited resources, in addition to holding previous executive positions at Medtronic, Bard and Fresenius Medical Care.

Diana is passionate about giving back to the community and has participated in several fundraising initiatives to promote awareness and action. An avid athlete, she has participated in the CIBC Run for the Cure and triathlons for the Shad Ireland Dialysis Foundation. She is a proud alumnus of the University of Notre Dame and strives to “Play like a Champion” every day.

James C. Temerty

Chairman, MOLLI Surgical

James C. Temerty C.M. is the founder and largest shareholder of Northland Power Inc. (TSX: NPI).

Before establishing Northland Power in 1987, he had a successful career in computer-related companies, building the world’s largest chain of Computerland franchises and guiding Softchoice Corporation to its position as a leading North American provider of software and hardware products.

Mr. Temerty’s entrepreneurial career has been recognized by the community in various ways, the most distinguished of which, was being awarded the Ernst and Young Entrepreneur of the Year Award for Canada in 2010.

In addition to Mr. Temerty's successful business ventures, he is a very active philanthropic member of his community locally, nationally and abroad. Mr. Temerty’s passion for giving back and helping others has been exhibited through his contributions of time, funding and guidance to the charitable and non profit sector.

Mr. Temerty has served on various boards over the years, including Chair of the Royal Ontario Museum Board of Governors, board member of the Royal Conservatory of Music, Chairman of the Advisory Council of the Kyiv Mohyla Business School in Kyiv, Co-chair of the Havergal Campaign, Director of the Sunnybrook Hospital Foundation and Founding Chairman of the National Advisory Council for the Ukrainian Canadian Congress, to name a few.

Mr. Temerty has been recognized for his philanthropic endeavours with many distinguished honours, In 2008, he was awarded the prestigious Order of Canada in recognition of his contributions to society. Mr. Temerty received the Queen Elizabeth II Diamond Jubilee Medal in 2012 to honour him for his contributions to his country. In 2013, Mr. Temerty was the first recipient of the Metropolitan Andrey Sheptytsky Medal, an award established to recognize contributions to the cause of Ukrainian-Jewish Understanding and Cooperation. He was honoured in 2015 by Ukrainian President Poroshenko with Ukraine’s Order of Yaroslav the Wise, which is the highest tribute Ukraine can confer to a foreign citizen who has not been a head of state. In 2015, Mr. Temerty and his wife, Louise, were honoured by Ryerson University with a joint degree of Doctor of Laws, Honoris Causa. And in June 2018, Mr. Temerty received the degree of Doctor of Laws, Honoris Causa by York University.

Paul Radchuck, MBA

Chief Financial Officer

Paul has an extensive investment banking background developed at leading financial advisory firms, including Morgan Stanley and most recently Lazard, serving clients at large cap and small/private companies.

He built on his early career as an engineer at Halliburton Company in Calgary.

Paul is responsible for leading alignment of our business and financial strategy to support our growth and strategic decision making.

Brian Keith

President, Sales & US Operations

Brian is a hospital and health care industry veteran with over 20 years of sales and executive leadership experience. He has held strategic positions at several medical device companies, including GE Healthcare and Samsung Health & Medical Division.

Prior to joining MOLLI Surgical, Brian led GE Healthcare’s US$180 million Women’s Health Ultrasound division, where he managed a team of over 100 field sales and applications employees, first line managers, operations and support personnel, successfully capturing 65% of the market. During his tenure at GE, he held several leadership roles, including General Manager Women’s Health Ultrasound, General Manager Point of Care Ultrasound and General Manager Government Accounts.

Brian is a graduate of the United States Naval Academy with a BS in Economics. While at the Academy, he served as captain of the lacrosse team, and earned All-American honors for three consecutive years.

Our Partner

Sunnybrook is home to Canada’s largest trauma centre with 1.3 million patients annually and fully affiliated with the University of Toronto.

Sunnybrook offers one of the largest, highly specialized breast cancer care teams in Canada.

The Louise Temerty Breast Cancer Centre provides patients with expanded facilities for breast care and fosters greater collaboration in the areas of breast imaging, clinical care, and research and clinical trials. 

What people are saying about MOLLI

The MOLLI system is easy to use and above all, very intuitive. Of particular value to me is the ability to generate and use accurate distances from the marker to achieve intended margins during a lumpectomy.

Dr. Nicole Look Hong, MD, M.Sc.Surgical Oncologist, Sunnybrook Health Sciences Centre

The MOLLI system is easy to use and the signal from the magnetic seed does not cross react with the Technetium-99 for the sentinel node.

Dr. Frances Wright, MD, M.Ed.Surgical Oncologist, Sunnybrook Health Sciences Centre

The MOLLI system allows for simple and easy pre-operative localization without the use of a cumbersome wire or radiation. It also alleviates the stress of scheduling the localization procedure relative to the OR schedule where the seed can be placed prior to surgery at a time and date that is convenient for both the patient and radiologist.

Dr. Mia Skarpathiotakis, BASc, MSc, MD, FRCPCRadiologist, Sunnybrook Health Sciences Centre

According to Sieu-Mui Luc Ong, a patient in the Phase I MOLLI study, when the magnet was implanted in her tumour, she barely noticed it. She returned two days later to Sunnybrook for the lumpectomy under anaesthetic and went home the same day. Mrs. Ong noted that there’s hardly even a mark on her breast.

Excerpt from Sunnybrook Magazine, Fall 2018

It will allow flexibility for treatment options. To me, this is precision therapy. We know exactly where the tumor is, we can take it out at the earliest stage and we can minimize damage to the body.

Dr. Calvin Law, MD, MPH, FRCSCChief, Edmond Odette Cancer Centre, Sunnybrook Health Sciences Centre and Regional Vice President, Cancer Care Ontario

The biggest potential opportunity of the MOLLI device is it allows us to take the next step in image guided therapeutics. It’s the right idea for better care. There’s no question it’s just better than the current approach.

Dr. Andy Smith, MD, MSc, FRCSC, FACSPresident and Chief Executive Officer, Sunnybrook Health Sciences Centre

See why MOLLI™ is the better choice for

precision surgery.

Request a Demo

Contact us

MOLLI Surgical Inc.
22 St. Clair Ave. E., Suite 1500
Toronto, ON, M4T 2S3, Canada
info@mollisurgical.com

Media inquiries, please contact
media@mollisurgical.com

Join us

We‘re growing and looking for talent.
Current Positions

Privacy Policy

Join our mailing list.

Stay Connected